Evidence map›Paper›PMID 21099107›Full record

ArticleThe Journal of clinical investigation2010

Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Mark R Schleiss

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mark R SchleissDepartment of Pediatrics, University of Minnesota Medical School, Center for Infectious Diseases and Microbiology Translational Research, Minneapolis, Minnesota, USA. schleiss@umn.edu
University of Minnesota Medical Center · US

Funding

Viral Immunomodulation and Rational CMV Vaccine DesignR01HD044864 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI GEBALLE, ADAM P., MCVOY, MICHAEL A · 2003 to 2015
$4.5M
VACCINES FOR PREVENTION OF EXPERIMENTAL CONGENITAL CMVR01HD038416 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SCHLEISS, MARK R. · 2000 to 2009
$2.2M
NICHD NIH HHS HD038416NICHD NIH HHS HD044864NICHD NIH HHS R01 HD038416NICHD NIH HHS R01 HD044864
6 · The paper itself

Abstract

The magnitude and durability of immunity to human cytomegalovirus (HCMV) following natural infection is compromised by the presence of immune modulation genes that appear to promote evasion of host clearance mechanisms. Since immunity to HCMV offers limited protection, rational design of effective vaccines has been challenging. In this issue of the JCI, Slavuljica and colleagues employ techniques to genetically modify the highly related mouse CMV (MCMV), in the process generating a virus that was rapidly cleared by NK cells. The virus functioned as a safe and highly effective vaccine. Demonstration of the ability to engineer a safe and highly effective live virus vaccine in a relevant rodent model of CMV infection may open the door to clinical trials of safer and more immunogenic HCMV vaccines.

Indexed as

AnimalsChromosomes, Artificial, BacterialCytomegalovirusCytomegalovirus InfectionsGenes, ViralGenetic EngineeringHerpesviridae InfectionsHumansKiller Cells, NaturalMiceMuromegalovirusViral VaccinesViral Vaccines

Identifiers

PMID21099107
PMCPMC2993604
OpenAlexW1991968686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.